

## SUPPORTING DOCUMENT - A

### Application for flexibility in the implementation of the Minimum Levels of Analysis (MLAs)

In accordance with Article 6 of the TDSSA and in compliance with Article 4.7.2 of the International Standard for Testing and Investigations (ISTI), *“WADA will approve the analysis of Samples for less than the Sample analysis menu specified in the Technical Document where it is satisfied that such an approach will lead to the most intelligent, effective and efficient use of available Testing resources”* and meet the criteria listed in Articles 3 and 6 of the TDSSA.

- a. If you are applying for flexibility in the implementation of the Erythropoiesis Stimulating Agents (ESAs) MLAs based on the implementation of the haematological module of an Athlete Biological Passport program (ABP), please answer questions 1 - 9.
- b. If you are applying for flexibility in the implementation of the MLAs based on other (non-ABP related) criteria, please answer questions 10-20.
- c. If you are applying for flexibility based on both the implementation of an ABP and on other (non-ABP related) criteria, please answer all questions.

Once your application is completed, please submit it to WADA via [tdssa@wada-ama.org](mailto:tdssa@wada-ama.org), together with latest version of your Risk Assessment, your Test Distribution Plan (TDP) and if applicable, your Registered Testing Pool (RTP).

#### Notes:

1. An ADO's application will automatically be pre-approved for flexibility in the implementation of the MLAs of the requested level (up to 50%) and for the sports or disciplines an ADO seeks flexibility for.
2. ADOs may submit an application for flexibility in the implementation of the MLAs for multiple sports and disciplines within the same application.
3. ADOs are encouraged to apply for flexibility in the implementation of the MLAs before the beginning of the testing year for which flexibility is requested.
4. An ADO's application is subject to review and WADA withholds the right to request further information from the ADO to justify the requested flexibility. WADA may withdraw or reduce the level of flexibility if the self-assessment was incorrectly answered or relevant documents requested are partially/not submitted within the requested timelines or are found not to be compliant with the ISTI. Please refer to Q47-51 of the TDSSA Supporting Document B for more information on the application for flexibility in the implementation of the MLAs.

## Questions for ADOs that apply for flexibility in the implementation of the ESAs MLAs based on the implementation of an ABP

1. Have you reviewed your TDP and confirmed that it is not possible to reallocate Tests/analyses in a way that better reflects the doping risks as per your Risk Assessment e.g. have you taken into account that the implementation of all 5% MLAs and GH MLAs is currently optional?

Yes

No

2. In which sport(s) and discipline(s) are you seeking flexibility in the implementation of the ESAs MLAs based on the implementation of an ABP, what % reduction are you seeking for each sport or discipline and what is the date the ABP started for each sport or discipline (see example below)?

	<b>Sport - Discipline</b>	<b>ESA Reduction sought</b>	<b>ABP Start Date</b>
<b>A.</b>	<i>Aquatics – open water</i>	<i>50%</i>	<i>January 2016</i>
<b>B.</b>			
<b>C.</b>			

3. Is your ABP program compliant with all applicable ABP Technical Documents and International Standards, including the International Standard for Testing and Investigations (ISTI) and the Technical Document for Athlete Passport Management Units (TD2019APMU)?

Yes

No

4. Is your ABP program managed by a WADA-approved Athlete Passport Management Unit (APMU) in accordance with the TD2019APMU?

Yes

No

4.1 If yes, please state which APMU you have partnered with.

5. Are all relevant ABP data, including Doping Control Forms (DCFs), APMU reports and Expert reviews available in ADAMS or another system approved by WADA, which permits oversight by WADA?

Yes

No

6. Is the distribution of the ABP Tests carried out according to the status of the Athlete's Passport, as well as any intelligence you may have access to and the recommendations of the APMU?

Yes

No

7. Are all RTP Athletes from those sports or disciplines with an ESAs MLA of 30% or greater (as identified in the TDSSA), that are referenced in your TDP, included in your ABP program?

Yes  N/A

No

8. Have you at a minimum planned annually an average of three blood ABP Tests across all *Athletes* from those sports or disciplines with

an ESAs MLA of 30% or greater, who are part of your RTP?

Yes  N/A

No

9. Please submit the latest version of your RTP including Athlete name, sport and discipline, together with this application, the latest version of your Risk Assessment and your TDP to WADA via [tdssa@wada-ama.org](mailto:tdssa@wada-ama.org).

**Questions for ADOs that apply for flexibility in the implementation of the MLAs based on other (non-ABP related) criteria**

10. Have you reviewed your TDP and confirmed that it is not possible to reallocate Tests/analyses in a way that better reflects the doping risks as per your Risk Assessment e.g. have you taken into account that the implementation of all 5% MLAs and GH MLAs is currently optional?

Yes

No

11. In which sport(s) and discipline(s) are you seeking flexibility in the implementation of MLAs based on other (non-ABP related) criteria, for what analysis type (GHRFs and/or ESAs), and what % flexibility (see example below)?

	<b>Sport - Discipline</b>	<b>ESA Reduction sought</b>	<b>GHRFs Reduction Sought</b>
D.	<i>Wrestling - all</i>	<i>50%</i>	<i>25%</i>
E.			
F.			

12. Are you prioritizing Target Testing for both In-Competition and Out-of-Competition?

Yes

No

12.1 If yes, please explain what strategies you use for Target Testing.

**13.** Are you collaborating with other ADOs in e.g. jointly deciding which athletes go in which ADO's RTPs and/or sharing Testing plans for Athletes of joint interest?

**Yes**

**No**

**13.1** If yes, please explain what elements of collaboration you engage in with other ADOs in relation to your Testing program.

**14.** Do you have mechanisms to gather intelligence?

**Yes**

**No**

**14.1** If yes, please explain.

**15.** Do you make use of the gathered intelligence in the implementation of your anti-doping program, including conducting investigations?

**Yes**

**No**

**15.1** If yes, please explain.

**16.** Do you collaborate with law enforcement authorities such as e.g. customs, police, etc. as part of sharing intelligence?

**Yes**

**No**

**16.1** If yes, please explain.

**17.** Do you implement alternative Testing strategies including the application of specific analysis for other Prohibited Substances and/or Prohibited Methods outside the scope of the TDSSA and that are not part of a standard urine analysis?

**Yes**

**No**

**17.1** If yes, please explain.

18. Do you have a Sample retention and Further Analysis policy?

Yes

No

18.1 If yes, please submit your Sample retention and Further Analysis policy to WADA via [tdssa@wada-ama.org](mailto:tdssa@wada-ama.org).

19. Do you correctly enter Doping Control Forms into ADAMS within 15 business days of Sample collection?

Yes

No

20. Please outline any other innovative anti-doping strategies you are currently implementing that support a more intelligent, effective and efficient use of your available Testing resources.

Please submit this application, together with all requested documents as part of this application to WADA via [tdssa@wada-ama.org](mailto:tdssa@wada-ama.org).